Third Party Funds Group - Sub project
Acronym: GeGe4Nephro
Start date : 01.11.2025
End date : 31.10.2028
Website: https://gege4nephro.eu/
Approx. 100,000 people in Germany live with chronic kidney disease and require regular dialysis and, in the long term, an organ transplant. Their care accounts for more than ten percent of healthcare expenditure. Kidney transplant recipients have a higher risk of cancer than the general population. Gender-specific differences in diagnosis, therapy, and aftercare are still not taken into account sufficiently. For example, women have up to a 20 percent lower chance of getting on the waiting list for a donor kidney, despite having a comparable or better prognosis after transplantation than men.
The goal of GeGe4Nephro is to develop an AI-supported prognosis model that helps physicians better assess the individual risk of complications after a kidney transplant, such as cancer, and to recommend personalized preventive measures, such as targeted skin cancer screenings.
The GeGe4Nephro consortium combines all relevant expertise for this purpose. The Charité – Universitätsmedizin Berlin (CHA) and the Universitätsklinikum Leipzig (UKL) contribute clinical expertise and transplant data, the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) is responsible for ethical guidelines, and the Hasso Plattner Institute for Digital Engineering (HPI) contributes AI methodological expertise. Justus Liebig University Giessen (JLU) and Labor Pachmann GmbH contribute state-of-the-art epi/genetic and molecular laboratory expertise. In addition, the consortium has a broad network of international partners consisting of – amongst others – patient and physician representatives, transplant centers, research, and industry representatives.
GeGe4Nephro aims to build an innovative tool for gender-specific, data-based medicine that sustainably optimizes the follow-up care of kidney transplant patients.